STOCK TITAN

GRI Bio (GRI) Form 4 Filings

GRI NASDAQ

Here are the Form 4 insider transactions from GRI Bio, Inc. (GRI) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A Form 4 covers the transactions officers, directors and large holders report, so if you follow GRI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GRI filings page.

Rhea-AI Summary

GRI Bio, Inc. director David Charles Baker received a grant of 3,935 stock options on November 4, 2026, with an exercise price of $1.43 per share. The options cover common stock, and his reported resulting position was 3,935 options.

Rhea-AI Summary

GRI Bio, Inc. director Camilla V. Simpson received a grant of 3,935 stock options on November 4, 2026, covering common stock at an exercise price of $1.43 per share. The options expire November 4, 2036.

Rhea-AI Summary

GRI Bio, Inc. director Roelof Rongen received a grant of 3,935 stock options on November 4, 2026, exercisable for common stock at $1.43 per share. The options vest in four equal quarterly installments and are fully vested on the first anniversary of the grant; they expire November 4, 2036. His directly held options following the grant totaled 3,935.

Rhea-AI Summary

GRI Bio, Inc. director David Leslie Szekeres received a direct stock option award covering 6,558 shares of common stock on November 4, 2026. The options have a $1.43-per-share exercise price and expire November 4, 2036. The reported post-award option holding is 6,558.